We build leadership teams for breakthrough companies. Take a look at some of our work. contact us to learn more.
Acucela is a clinical-stage biotech company that specializes in discovering and developing novel drugs to treat and slow the progression of sight-threatening ophthalmic diseases.
- Member, Board of Directors
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals.
- Member, Board of Directors
Allergan is a multi-specialty health care company with an emphasis in eye care, aesthetics, and neurology. (Acquired by Actavis)
- VP Neurology
- Sr. Director Clinical Development - Neuorology
- Sr. Director Clinical Affairs - Retina
- Sr. Medical Director
Angion is a late-stage biopharmaceutical company focused on
the discovery, development, and commercialization of novel
small molecule therapeutics to address acute organ injuries and
- VP Program Management, Alliance Management & Quality Assurances
Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the core areas of neurology, orphan and specialty medicines.
- VP Controller
- Director Access & Specialty Pharma Marketing
Cascadian Therapeutics is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. (Acquired by Seattle Genetics)
- Sr. VP Regulatory, Quality
Confluence Life Sciences is a technology-based company focusing on rational drug design to identify proprietary, mechanistically novel drugs.
- Executive Chairman, Board of Directors
Graybug Vision is developing novel products for the treatment of people with ocular diseases. The Company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases.
- VP Clinical Operations
Immusoft's mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™).
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives.
- Head of Innovation
- VP Corporate Development
- Group Leader
Kalytera is advancing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like compounds to address important unmet market needs. Kalytera’s drug candidates are cannabinoid and endocannabinoid-like compounds that strive to improve upon first-generation cannabis products and their analogues by increasing drug specificity while simultaneously reducing or eliminating unwanted side effects.
- President, COO, & CFO
Kedalion Therapeutics is a clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications.
- President & CEO
Med-Pharmex manufactures quality generic human and veterinary drug products.
- VP Operations
Medicines360 is a nonprofit global women’s health pharmaceutical company with a mission to remove cost as a barrier to health by developing and providing affordable Women’s Health products.
- VP Marketing
Millendo Therapeutics is focused on developing a broad portfolio of first-in-class, disease-modifying treatments for endocrine diseases caused by hormone dysregulation.
- Sr. VP Regulatory
Rubryc Therapeutics is a biotechnology company that integrates chemistry and computation to discover and develop antibody-based drugs with un-precedented epitope selectivity.
Santen specializes in ophthalmic and anti-rheumatic pharmaceuticals.
- VP Finance (Promoted to Global CFO)
Sirenas is a company with a validated drug development platform designed to bring unparalleled chemical diversity to high-value therapeutic areas. The company currently specializes in the discovery and development of differentiated payloads for antibody drug conjugates and of new chemical entities in immuno-oncology.
- Executive Chair
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface.
- Chief Scientific & Innovation Officer
Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.
- VP Head, Medical Affairs
- VP Human Resources
- Sr. Director Project Management - CMC
- Sr. Director Quality
Vascular Therapies is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring an AV fistula for dialysis.
- Sr. VP Regulatory & Quality
Vertex Pharmaceuticals uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs.
- VP Integrated QMS Oversight
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
- Sr. VP Clinical Development